Pfizer has secured global licensing rights, excluding China, for 3SBio’s dual-target cancer therapy SSGJ-707. This agreement marks a significant collaboration between the two companies, with Pfizer gaining access to a promising new cancer treatment. SSGJ-707 is a novel, dual-targeting antibody-drug conjugate (ADC) that has shown potential in treating various types of cancer.
Under the terms of the agreement, Pfizer will be responsible for the development, manufacture, and commercialization of SSGJ-707 worldwide, except in China, where 3SBio will retain the rights. 3SBio will receive an upfront payment, as well as potential milestone payments and royalties on future sales.
SSGJ-707 is designed to target two specific proteins, CD19 and CD22, which are commonly expressed in certain types of cancer, including B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. The dual-targeting approach is intended to improve the efficacy and safety of the treatment, as well as reduce the risk of resistance.
The ADC technology used in SSGJ-707 involves linking a cytotoxic drug to a monoclonal antibody, which is designed to selectively target and kill cancer cells. This approach has shown promise in treating a range of cancer types, including hematological malignancies and solid tumors.
Pfizer’s acquisition of the global licensing rights for SSGJ-707 outside of China is a strategic move to strengthen its oncology portfolio. The company has been actively expanding its presence in the cancer treatment market, with a focus on innovative therapies that can improve patient outcomes.
The partnership with 3SBio is expected to accelerate the development of SSGJ-707, with Pfizer’s global resources and expertise enabling the therapy to reach a broader patient population. 3SBio, on the other hand, will benefit from Pfizer’s commercialization capabilities, while retaining the rights to the therapy in China.
This collaboration highlights the growing trend of partnerships between pharmaceutical companies and biotech firms, as they seek to leverage each other’s strengths to bring innovative treatments to market. The deal also underscores the increasing importance of China as a major player in the global biopharmaceutical industry, with companies like 3SBio emerging as key partners for international pharmaceutical companies. Overall, the licensing agreement between Pfizer and 3SBio has the potential to bring a promising new cancer therapy to patients worldwide, and marks an important step forward in the fight against cancer.